Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

Chong Ma; Jing Feng; Rahnuma Wahid; Spyros Chalkias; Darin Edwards; Bethany Girard; Rituparna Das; Honghong Zhou; Lingyi Zheng

doi:10.1080/21645515.2026.2679783

June 1, 2026Human Vaccines & ImmunotherapeuticsOpen Access

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to analyze immune correlates related to the mRNA-1283 vaccine's efficacy against COVID-19 variants.
Evaluated neutralizing antibody (nAb) levels against COVID-19 variants.
Correlated nAb levels with protection outcomes in vaccinated individuals.
nAb levels against variants were significantly associated with stronger protection from COVID-19 (p<0.001).
Protection was notably stronger for variants similar to circulating strains.
Findings underscore the importance of nAb levels in vaccine effectiveness.

Implication

Analyzes immune responses of next-generation mRNA-1283 vaccine against COVID-19 variants, indicating efficacy.

Abstract

< .001), respectively. These findings indicate that nAb levels, particularly against variants antigenically similar to circulating strains, remain associated with stronger contemporaneous protection against COVID-19.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ma et al. (2026) studied this question.

synapsesocial.com/papers/6a1fc56bdee9eb8c0dce6e6b https://doi.org/10.1080/21645515.2026.2679783

View Full Paper

Ask AI

Bookmark

Share

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

Key Points

Implication

Abstract

Discussion

Cite This Study

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading